In a study involving patient-derived xenograft (PDX) models of BC with FGFR genetic abnormalities, significant antitumor effects were found, particularly in models with FGFR2 amplification and FGFR2 Y375C mutations. The gene discussed is FGFR2; the disease is breast cancer.